Sonrai Analytics (Sonrai), a leader in AI precision medicine, today announced the completion of its latest round, led by Beach Equity Investments (BEI), a UK private equity company. The round also included additional funds from incumbent investors.
The investment has coincided with the hire of ex-J&J business leader, Chris Brooks, as Chief Commercial Officer. Chris will be leading the commercial expansion of Sonrai, which added data and foundational model access to its market leading proprietary AI precision medicine platform.
The investment and expansion of the leadership team mark a significant milestone for Sonrai. Sonrai will now look to build on its position as a leading supplier of AI and data, with a focus on expanding commercial reach and delivering greater value to precision medicine leaders.
Prof. Darragh McArt, CEO and Founder, Sonrai commented “We are really proud of the progress we are making. The combination of the new funding and Chris joining our team is a huge vote of confidence in the momentum we have built. The team is excited to continue to lead the provision of service to those developing precision medicines with our cutting-edge AI and data-driven insights.”
“I’m thrilled to be joining Sonrai at such a pivotal moment in its growth journey.” said Chris Brooks, CCO, Sonrai. “The company’s technology and vision are incredibly compelling, and I’m looking forward to working with the team to scale our commercial efforts, deepen partnerships, and deliver even more value to customers across pharma and biotech, accelerating discovery.”
Tommy O’Sullivan, Managing Partner, Beach Equity Investments commented “We are delighted to be working with Sonrai at such an exciting period of their expansion. Sonrai has positioned itself as the leader in the support required to develop precision medicines and look forward to supporting Darragh and the team as they continue to push forward.
Sonrai
Sonrai operates at the forefront of transforming complex, multi-modal data into actionable insights that accelerate drug discovery and development.
Sonrai supports precision medicine leaders by providing its proprietary Sonrai Discovery platform, a full service solution for managing its clients’ data. The platform includes AI-driven imaging workflows and deep biological interpretation capabilities, enabling research teams to make faster, more accurate decisions, from identifying promising targets to prioritizing the most viable therapeutics. The platform now also provides access to data to support and enrich results analysis and a range of multimodal modelling functionality.
Chris Brooks
Chris joins the leadership team to drive commercial strategy, grow market presence, and lead customer engagement as the company expands its reach in the precision medicine space. Chris comes with over 15 years commercial experience in the life sciences sector, both in scale up and large enterprise businesses. The majority of his career has been spent at Johnson & Johnson, leading commercial teams across sales and marketing functions in multiple therapeutic areas and geographies.
Sync NI's Summer 2025 magazine celebrates women in tech across Ireland as we continue to encourage more women to enter the thriving sector and address the current gender imbalance. Read the Summer 2025 Sync NI Magazine online for free here.
